Loading

Journal of Endocrinology, Diabetes and Obesity

IL-35 Levels and Their Association with Thyroid Function Tests in Hashimoto’s Thyroiditis

Short Communication | Open Access | Volume 9 | Issue 1

  • 1. Department of Internal Medicine, University of Health Science, Ankara City Hospital, Ankara, Turkey
  • 2. Department of Internal Medicine, Necmettin Erbakan University, Konya, Turkey
+ Show More - Show Less
Corresponding Authors
Osman Inan, Department of Internal Medicine, University of Health Science, Ankara City Hospital, Ankara, Turkey, Tel: +905054643065; Fax: +903125850000.
Abstract

Background: In this study, it was aimed to examine interleukin-35 (IL-35) levels and their association with thyroid function tests in Hashimoto’s thyroiditis (HT).

Methods: Included in the study were 128 individuals, between 18 and 65 years of age, who had been newly diagnosed with HT (euthyroid, subclinical hypothyroidism and overt hypothyroidism) and 38 health controls who had no known diseases or drug use.

Result: No significant difference was determined between the groups in terms of the IL-35 levels (P = 0.285), although in the in-group comparisons, the IL-35 levels were found to decrease progressively towards overt hypothyroidism. In the in-group comparisons, however, a statistically significant difference was determined between the control group and the overt hypothyroidism group (550.05 ± 411.50 vs. 369.80 ± 253.33; P = 0.046). When the patient groups were grouped according to their thyroid stimulating hormone values, a significant difference was determined between the groups with a threshold value of ≥6 uIU/ mL and those below it, in terms of the IL-35 levels (P = 0.043). When two groups were created, comprising those with a threshold value of ≥10 uIU/mL and those below it, it was observed that there was a more significant difference between the groups in terms of the IL-35 levels (P = 0.024). As a result of the correlation analysis performed by taking into account the controllable factors (smoking, diabetes mellitus, hypertension, and body mass index), a low-significant correlation was determined between the IL-35 levels and antithyroid peroxidase (P = 0.029).

Conclusion: In conclusion, in this study, it was determined that the IL-35 levels, an antiinflammatory cytokine involved in HT, decreased progressively from the euthyroid patient group towards the overt hypothyroidism group.

Keywords
  • Hashimoto’s thyroiditis
  • Antiinflammatory cytokine
  • Autoimmunity
  • IL-35
Citation

Inan O, Karakurt F (2021) IL-35 Levels and Their Association with Thyroid Function Tests in Hashimoto’s Thyroiditis. J Endocrinol Diabetes Obes 9(1): 1123.

INTRODUCTION

Hashimoto’s thyroiditis (HT) was originally defined by Japanese surgeon Dr. Hakaru in 1912, in 4 patients with chronic thyroid disease and enlarged thyroid glands [1]. HT is the most common global cause of hypothyroidism in iodinesufficient areas [2]. Furthermore, it is the most common cause of hypothyroidism in adults, with a recently increasing incidence [3,4]. HT is an autoimmune thyroid disease that is characterized by diffuse lymphocytic infiltration of the thyroid gland, which is clearly revealed by the presence of circulating thyroid autoantibodies and clinical or immunological co-existence with other autoimmune diseases [5,6]. This disease is also called chronic autoimmune thyroiditis [7].

Cellular and humoral immunity together play a role in the pathogenesis of HT and the activation of CD4 (+) T lymphocytes specific to thyroid antigens is thought to be the first step in its pathogenesis [8]. There is a cell-cell interaction and cytokine control, which are mediated by regulatory (or suppressor) cells (CD4+CD25+Foxp3+), or so called Treg cells, in the immune system. Treg cells secrete antiinflammatory interleukin-10 (IL-10) and IL-35. HT patients have reduced or inadequately functional regulatory cells [9]. Suppressor T lymphocyte dysfunction has been suggested to be important in the pathogenesis of this event and the pathology has been thought to be caused by an impairment in immune tolerance [10-12]. A reduced number of cells with suppressor properties leads to a reduction in the tolerance of the organism to self-tissue antigens. As a result of this defect, suppressor CD8+ T lymphocytes cannot suppress helper CD4+ T lymphocytes. Activated helper CD4+ T lymphocytes interact with B lymphocytes and these activated B lymphocytes then produce antibodies against several thyroid antigens [13,14].

IL-35 is a newly described cytokine with immunosuppressive and antiinflammatory effects [15]. In recent studies, the role of IL-35 in autoimmunity has been demonstrated and IL-35- expressing Treg cells and IL-35 were required for an optimal suppressive effect [16]. In the literature review conducted herein, a limited number of studies were encountered on the relationship between IL-35 and HT.

It was therefore aimed in this study to examine the IL-35 levels and their relationship with thyroid function tests.

MATERIAL AND METHODS

Study population

This study was planned at the Department of Internal Diseases of the Turgut Ozal University Faculty of Medicine. The study was begun following ethics committee approval dated 13/09/2012 and numbered B30 2 FTH 0200000/1099. Included in the study were 128 individuals, between 18 and 65 years of age, who had been newly diagnosed with HT (euthyroid, subclinical hypothyroidism, and overt hypothyroidism) and 38 health controls who had no known diseases or drug use.

Those who were 65 years of age, pregnant, had congenital hypothyroidism, hypothyroidism secondary to surgery, hypothyroidism secondary to drug use, evidence of a known acute or chronic infection, malignancy, acute-chronic kidney failure, chronic liver failure or did not sign the informed consent were excluded from the study.

While establishing the diagnosis of HT, clinical findings, physical examination, positive autoantibodies [elevated antithyroglobulin (anti-TG) (>34 IU/mL) and/or antithyroid peroxidase (anti-TPO) (>115 IU/mL)], and ultrasonographic findings (heterogenous appearance of thyroid parenchyma and reduced echogenicity) were taken into consideration, and a biopsy was not considered necessary. The period that was compensated by a mildly elevated thyroid stimulating hormone (TSH) (4.5 mU/L-10 mU/L) and when minor symptoms were observed only in some patients was defined as subclinical hypothyroidism, whereas the period when the TSH were elevated above 10 mU/L and the symptoms became more prominent was defined as overt hypothyroidism.

Sociodemographic characteristics, personal histories, family histories, and smoking-drinking and other habits of the patients and healthy volunteers included in the study, as well as the presence of a systemic disease or history of drug use, were investigated.

Biochemical analysis

For analysis of the biochemical parameters and studying the IL-35 levels of all of the participants, following a 12-h fasting, one tube of blood sample was collected from the antecubital vein before 10:00 A.M. After the collected blood samples were centrifuged at 5000 rpm, the serum and plasma samples were separated. After that, following the collection of blood samples of all of the participants, the IL-35 levels were studied at the same laboratory. Fasting blood glucose, routine biochemical work-ups, and lipid profile were measured spectrophotometrically using a Roche Cobas C501 device (Roche Group, Basel, Switzerland). Fasting insulin, free triiodothyronine (T3) (sT3 3), free thyroxine (T4) (sT4) and TSH levels were measured via the Enzyme Chemiluminescence Immunoassay (ECLIA) method in a Roche Cobas 6000 module device. Anti-TG and anti-TPO were studied via the ECLIA method in a Roche Cobas e 601 device.

IL-35 measurement

Serum IL-35 levels were measured via the sandwich ELISA method using the Cusab?o Biotech commercial kit (Cusabio Technology LLC, Houston, TX, USA; Catalogue no: CSB-E13126h). The sensitivity of this method was 15.6 pg/mL, intra-assay precision was <8%, and inter-assay precision was <10%, respectively.

Ultrasonographic examination

The HD15 PureWave Ultrasound System (Philips Medical Systems, Bothell, WA, USA) was used for ultrasonographic evaluation of the thyroid gland.

Statistical analysis

For the statistical analyses, IBM SPSS Statistics for Windows 20.0 (IBM Corp., Armonk, NY, USA) was used. Conformity of the variables to normal distribution was examined using the ShapiroWilk test. Descriptive analyses were given as the mean ± standard deviation for normally distributed variables and as the median and minimum-maximum values for non-normally distributed variables. Homogeneity of the groups and inter-group difference analyses were performed using one-way ANOVA and the least significant difference post-hoc test. For the inter-variable correlation analysis, the Pearson correlation tests were used. P < 0.05 was considered as statistically significant.

RESULT

Sociodemographic and laboratory characteristics of the groups are represented in Table 1;

Table 1: Clinical demographic and laboratory findings of the study population.

Variables Control n: 38 Euthyroid n: 59 Subclinical n: 39 Overt hypothyroidism n: 30 P-value
F/M (n) 28/10 (38) 47/12 (59) 30/9 (39) 23/7 (30) 0.927
  mean ± SD mean ± SD mean ± SD mean ± SD  
Age 39.29 12.99 39.83 11.47 40.05 11.58 36.30 11.63 0.544
BMI 27.76 3.94 25.45 3.31 27.52 4.92 25.27 4.01 0.006
Smoking (n)    2    2    2    1 0.952
HT (n)    2    9    7    5 0.363
DM (n)    3    7    6    6 0.161
  mean ± SD mean ± SD mean ± SD mean ± SD  
TSH (uIU/mL) 1.70 0.67 1.71 0.78 7.59 1.53 27.17 27.13 0.000
ST4 (ng/dL) 1.18 0.16 1.23 0.28 1.00 0.15 0.92 0.17 0.000
ST3 (pg/mL) 2.91 0.45 2.98 0.38 2.84 0.33 2.73 0.32 0.035
TPOAb (IU/mL) 10.8 12.8 479.2 495.1 402.2 379.5 457.6 371.1 0.000
TG Ab (IU/mL) 7.04 4.95 146.7 265.9 101.9 119.0 214.4 246.1 0.002
TC (mg/dL) 204.33 44.3 201.48 45.83 207.76 36.82 195.02 37.48 0.732
TG (mg/dL) 139.67 73.10 106.35 51.90 132.59 76.70 108.36 48.66 0.058
HDL (mg/dL) 50.55 12.97 56.63 15.46 51.13 12.83 53.62 9.14 0.152
LDL (mg/dL) 125.89 36.89 123.51 44.49 130.24 35.14 118.15 34.79 0.701

the groups were similar with regards to gender, age distribution, smoking status, number of individuals with hypertension, and diabetes mellitus (DM). The body mass index (BMI) was similar between the healthy control group and the subclinical hypothyroidism group; however, the levels in these groups significantly differed from the euthyroid and overt hypothyroidism groups (P = 0.006). When the patient groups and the control group were compared, the groups were similar in terms of total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglyceride levels.

Although there was no significant difference between the groups in terms of IL-35 levels (P = 0.285), it was observed in the in-group comparisons that the IL-35 levels decreased progressively towards overt hypothyroidism. In the in-group comparisons, however, a statistically significant difference was determined between the control group and the overt hypothyroidism group (550.05 ± 411.50 vs. 369.80 ± 253.33; P = 0.046) (Table 2).

Table 2: IL-35 levels of the study groups.

  Control
n: 38
Euthyroid
n: 59
Subclinical
n: 39
Overt hypothyroidism
n: 30
Mean ±SD Mean ±SD Mean ±SD Mean ±SD
IL-35 level 550.05 411.50 486.84 360.83 475.17 400.53 369.80 253.33
  Full Group CG EG CG SCHG KG OHG EG SCHG EG OHG SCHG OHG
P-value 0.285 0.408 0.372 0.046 0.878 0.156 0.238

When the patient groups were grouped according to their TSH values, a significant difference in the IL-35 levels was determined between the groups, with a threshold value of ≥6 uIU/mL and that below it (P = 0.043). When two groups were created, comprising the group with a threshold value of ≥10 uIU/mL and that below it, it was determined that the IL-35 levels more significantly differed between the groups (P = 0.024) (Table 3) (Figure 1).

Relationship with IL-35 according to the TSH ?6 and TSH ?10 levels.

Figure 1 Relationship with IL-35 according to the TSH ≥6 and TSH ≥10 levels.

Table 3: Relationship with IL-35 according to the TSH ≥6 and TSH ≥10 levels.

                           TSH  N Mean ± SD P-value
IL-35 level (ng/dL) ≥6 61 404.81 327.54 0.043
<6 105 519.60 384.58
≥10 30 369.80 253.33 0.024

When the correlation analyses of IL-35 levels with the thyroid function tests were performed, a negative correlation of the IL-35 levels with the TSH, sT4 , and anti-TG levels was determined; however, no statistically significant difference was obtained. When the correlation analysis was performed by taking into account the controllable factors (smoking status, DM, hypertension, and BMI), a low-significant correlation was determined between the IL-35 and anti-TPO (P = 0.029) (Table 4).

Table 4: Correlation relationship between the IL-35 levels and thyroid function tests.

  TSH sT4 sT3 Anti-TPO Anti-TG
IL-35 level r
P-value
–0.050
0.524
–0.072
0.355
0.025
0.748
0.152
0.051
–0.099
0.202
Controllable variables (smoking status, DM, hypertension, BMI) r
P-value
–0.063
0.430
–0.067
0.404
0.052
0.518
0.175
0.029
–0.096
0.232

 

DISCUSSION

While among the HT groups the IL-35 levels decreased progressively from the euthyroid group towards the overt hypothyroidism group in this study, a statistically significant difference could not be reached between the groups. The IL-35 levels were determined to be higher in the control group when compared to the overt hypothyroidism group. No significant difference was determined between the IL-35 levels and the thyroid function tests and autoantibodies.

Considering that IL-35 is an antiinflammatory cytokine that is secreted by Treg cells, it was hypothesized that it may be involved in development of HT. Because HT is an autoimmune disease and lymphocytic infiltration of the thyroid gland is crucial in its histopathogenesis, a potential reduction in the secretion of IL35, due to a reduced number and the function of Treg cells in HT and consequently, reduced antiinflammatory effectiveness, may be associated with lymphocytic infiltration of the thyroid gland. Thus, the role of IL-35 in autoimmunity has been demonstrated in recent studies [16], and it was shown in different experimental model systems that adaptively transferred iTR35 cells have effectively suppressed autoimmune diseases. In addition, in in vivo mice models, it has been demonstrated that, when IL35 derivatives were obtained from natural Treg cells, these cells induced iTR35-secreting cells while suppressing T cells. It has been proven in different studies that IL-35 regulates T cell activity and the suppression of T cell proliferation following the administration of recombinant IL-35 [18]. 

In this study, the IL-35 levels in HT we examined. No significant difference was determined between the groups in HT, although a reduction in the IL-35 levels with a progression towards the overt hypothyroidism group was observed in the in-group comparisons. In the in-group comparisons, however, a statistically significant difference was determined between the control group and the overt hypothyroidism group.

Hypothetically, a reduction in the IL-35 levels was expected with progression towards the overt hypothyroidism in HT. Hence, in this study, the reduction of the IL-35 levels with progression towards the overt hypothyroidism group, although not statistically significant, supported this hypothesis. When the patient groups were re-created using a threshold value for TSH, the resulting outcome became another point that supported this hypothesis. Nevertheless, when two groups were created by taking the threshold value for TSH as 6, <6 uIU/mL and ≥ 6 uIU/mL, it was observed that the IL-35 levels were statistically significantly reduced in the group with TSH ≥6 uIU/mL. When the groups were re-created using the TSH value as 10; however, it was found that the statistically significant reduction became more prominent. Based on this result, it can clearly be stated that the IL-35 levels reduced with progression towards manifestations of overt hypothyroidism in HT and that the development of an autoimmune process and the progression of the autoimmune process in HT may be closely associated with the reduction of the IL-35 levels.

In the literature, although there are studies regarding the IL35 levels in experimental models and animal studies, the number of studies regarding human serum IL-35 levels in autoimmune diseases is insufficient.

The small number of patients and cross-sectional design of this study were the major limitations. Moreover, the failure to study additional inflammatory parameters to determine the relationship of the IL-35 levels with antibodies in the HT group was another limitation.

In conclusion, in this study, it was determined that the IL-35 levels, an antiinflammatory cytokine involved in HT, decreased progressively from the euthyroid patient group towards the overt hypothyroidism group. For a better understanding of whether the IL-35 levels are involved in etiopathogenesis of HT and whether they have a relationship with autoantibodies, studies with a higher number of participants are required.

REFERENCES

1. R Volpe. The life of Hashimoto, Hakaru. Autoimmunity. 1989; 3: 243- 245.http://R Volpe. The life of Hashimoto, Hakaru. Autoimmunity. 1989; 3: 243- 245.

2. Larsen PR, Davies TF. Hypothyroidism and thyroiditis. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS (eds). Williams Textbook of Endocrinology (10th ed). Philadelphia: WB Saunders. 2002; 432-449.

3. Baker JR Jr. Autoimmune endocrine disease. JAMA.1997; 278: 1931- 1937.

4. Birinci N. Hashimoto tiroiditli çocuk hastalar?n demografik, klinik ve prognostik özellikleri. Ondokuz May?s Üniversitesi T?p Fakültesi, Çocuk Sa?l??? ve Hastal?klar? Uzmanl?k Tezi, Samsun. 2009.

5. Kolo?lu endokrinoloji temel ve klinik II. Bask? 2005 Prof. Dr. Gürbüz Erdo?an editörlü?ünde Prof.Dr.Nilgün Baykal sayfa. 271.

6. Volpe R. Autoimmune thyroiditis. In: Braverman LE, Utiger RD.Werner and ingbar’s the Thyroiditis. 6th ed. Philadelphia: Lippincott. 1991; 921-923.

7. Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. The New England Journal of Medicine. 1996; 335: 99-107.

8. Cappa M, Bizzarri C, Crea F. Autoimmune thyroid diseases in children. J Thyroid Res. 2010; 2011: 675-703.

9. Pathogenesis of Hashimoto’s Thyroiditis, Uptodate. 2013.

10. Tandon N, Metcalfe RA, Barnett D, Wheetman AP. Expression of the costimulatory molecule B7/BB1 in autoimmune thyroid disease. QJ Med. 1994; 87: 231-236. 

11. Greiner DL, Handler ES, Nakano K, Mordes JP, Rossini AA. Absence of the RT-6 T cells in diabetes-prone BB/W rats. J Immunol. 1986; 136: 148-151.

12. Martin A, Davies TF. T cells and human autoimmune thyroid disease: emerging data show lack of need to invoke suppressor T cell problems. Thyroid. 1992; 2: 247-261.

13. Colin M. Dayan, Gilbert Daniels, M.D. Chronic Autoimmune Thyroiditis. 2006; 335.

14. Karakurt F. Hashimoto tiroiditi hastalar?nda adiponektin düzeyleri üzerine parp-1 gen polimorfizmlerinin etkisinin ara?t?r?lmas?. ?stanbul Üniversitesi sa?l?k Bilimleri Enstitüsü, T?bbi Biyoloji Yüksek Lisans Tezi, ?stanbul, 2012.

15. Collison LW, Vignali DAA. Interleukin-35: odd one out or part of the family? Immunol Rev. 2008; 226: 248-262.

16. Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA. Cutting edge: human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol. 2011; 186: 6661-6666.

17. Mai J, Wang H, Yang XF. Th 17 cells interplay with Foxp3+ Tregs in regulation of inflammation and autoimmunity. Front Biosci. 2010; 15: 986-1006.

18. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007. 450: 566-569.

Inan O, Karakurt F (2021) IL-35 Levels and Their Association with Thyroid Function Tests in Hashimoto’s Thyroiditis. J Endocrinol Diabetes Obes 9(1): 1123.

Received : 15 Mar 2021
Accepted : 24 Mar 2021
Published : 26 Mar 2021
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X